Inkampani yobuchwepheshe bezokwelapha egxile ekuthuthukiseni ubuchwepheshe obusha bokuhlonza umdlavuza kusenesikhathi, namuhla imemezele imiphumela emisha yocwaningo. Ucwaningo lomtholampilo lomdlavuza wesibindi lubonise amandla amakhulu e-biomarker entsha ye-DNA methylation-based ye-LAM ukuthola i-hepatocellular carcinoma (HCC) Ukuzwela kokutholwa kungamaphesenti angama-95 kanti imininingwane ethile ingu-97.5%.
Kulolu cwaningo, amasampula esitokisini sezifundo ze-130 aqoqwe, okuhlanganisa: izihloko ze-60 ezitholakala ukuthi zine-hepatocellular carcinoma (isigaba I kuya ku-IV), izifundo ze-30 ezingenaso isifo sesibindi, Izihloko ze-10 ezitholwe zinesifo sesibindi esibucayi kanye nezihloko ze-30 ezitholakala nomdlavuza webele, umdlavuza we-colorectal noma umdlavuza wamaphaphu. I-DNA yakhishwa kusampula, i-DNA yashintshwa nge-bisulfite, futhi i-DNA methylation yalinganiswa kusetshenziswa isiteji se-IvyGene. Ngemva kokuqeda ukuqoqwa kwedatha nokuhlaziywa kwawo wonke amasampuli, vala amehlo amasampula ukuze ubale ukusebenza kokuhlolwa.
A total of 57 of the 60 samples taken from patients with hepatocellular carcinoma were correctly identified, with an overall calculated sensitivity of 95%. The sensitivity difference between detecting stage I and stage IV hepatocellular carcinoma was small (range 89% to 100%). Of the samples taken from cancer patients other than liver cancer, 90% of breast cancer samples, 80% of umdlavuza colorectal samples, and 90% of lung cancer samples were correctly identified as non-liver cancer, and the total calculated specificity was 87%.
